Li JB, Jiang J, Xue L, Zhao S, Liu HQ. Clinical efficacy of Baijin pills in the treatment of generalized tonic-clonic seizure epilepsy with cognitive impairment. World J Psychiatry 2024; 14(6): 938-944 [PMID: 38984341 DOI: 10.5498/wjp.v14.i6.938]
Corresponding Author of This Article
Hong-Quan Liu, MD, Chief Doctor, Chief Physician, Department of Neurology, The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 100 Cross Street, Hongshan Road, Nanjing 210000, Jiangsu Province, China. hongquanliu0305@163.com
Research Domain of This Article
Psychology, Development
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jun 19, 2024 (publication date) through Mar 5, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Li JB, Jiang J, Xue L, Zhao S, Liu HQ. Clinical efficacy of Baijin pills in the treatment of generalized tonic-clonic seizure epilepsy with cognitive impairment. World J Psychiatry 2024; 14(6): 938-944 [PMID: 38984341 DOI: 10.5498/wjp.v14.i6.938]
World J Psychiatry. Jun 19, 2024; 14(6): 938-944 Published online Jun 19, 2024. doi: 10.5498/wjp.v14.i6.938
Clinical efficacy of Baijin pills in the treatment of generalized tonic-clonic seizure epilepsy with cognitive impairment
Hong-Quan Liu, Shuai Zhao, Lian Xue, Jing Jiang, Jing-Bo Li
Jing-Bo Li, Jing Jiang, Lian Xue, Shuai Zhao, Hong-Quan Liu, Department of Neurology, The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210000, Jiangsu Province, China
Jing-Bo Li, Jing Jiang, Lian Xue, Shuai Zhao, Hong-Quan Liu, Department of Neurology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210000, Jiangsu Province, China
Author contributions: Li JB and Liu HQ contributed equally to this work; Li JB, Jiang J, Xue L, Zhao S and Liu HQ designed the research study; Li JB, Jiang J, Xue L, Zhao S and Liu HQ performed the research; Jiang J, Xue L, Zhao S contributed new reagents and analytic tools; Li JB and Liu HQ analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.
Supported byJiangsu Province Phase 6 "333 Project", No. BRA202201.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Committee of the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine Ethics Committee.
Clinical trial registration statement: Clinical trials registered in researchregistry (www.researchregistry.com).
Informed consent statement: All study participants, or their legal guardian, provided written consent prior to study enrollment.
Conflict-of-interest statement: Dr. Liu has nothing to disclose.
Data sharing statement: There is no additional data available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Corresponding author: Hong-Quan Liu, MD, Chief Doctor, Chief Physician, Department of Neurology, The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 100 Cross Street, Hongshan Road, Nanjing 210000, Jiangsu Province, China. hongquanliu0305@163.com
Received: March 1, 2024 Revised: April 22, 2024 Accepted: April 25, 2024 Published online: June 19, 2024 Processing time: 110 Days and 5.3 Hours
Abstract
BACKGROUND
The generalized tonic-clonic seizure (GTCS) is the most usual variety of epileptic seizure. It is mainly characterized by strong body muscle rigidity, loss of consciousness, a disorder of plant neurofunction, and significant damage to cognitive function. The effect of antiepileptic drugs on cognition should also be considered. At present, there is no effective treatment for patients with epilepsy, but traditional Chinese medicine has shown a significant effect on chronic disease with fewer harmful side effects and should, therefore, be considered for the therapy means of epilepsy with cognitive dysfunction.
AIM
To investigate the clinical efficacy of Baijin pills for treating GTCS patients with cognitive impairment.
METHODS
This prospective study enrolled patients diagnosed with GTCS between January 2020 and December 2023 and separate them into two groups (experimental and control) using random number table method. The control group was treated with sodium valproate, and the experimental group was Baijin pills and sodium valproate for three months. The frequency and duration of each seizure, the Montreal Cognitive Assessment Scale (MoCA), and the Quality of Life Rating Scale (QOLIE-31) were recorded before and after treatment.
RESULTS
There were 85 patients included (42 in the control group and 43 in the experimental group). After treatment, the seizure frequency in the experimental group was significantly reduced (P < 0.05), and seizure duration was shortened (P < 0.01). The total MoCA score in the experimental group significantly increased compared to before treatment (P < 0.01), and the sub-item scores, except naming and abstract generalization ability, significantly increased (P < 0.05), whereas the total MoCA score in the control group significantly decreased after treatment (P < 0.05). The QOLIE-31 score of the experimental group increased significantly after treatment compared to before treatment (P < 0.01).
CONCLUSION
Baijin pills have a good clinical effect on epilepsy with cognitive dysfunction.
Core Tip: Generalized tonic-clonic seizure can induce the most significant damage to cognitive function. The impact of antiepileptic drugs on cognition should not be ignored. At present, there is no special treatment for patients with epilepsy, and traditional Chinese medicine has shown a significant effect on chronic diseases with fewer harmful side effects; therefore, traditional Chinese medicine should be considered for the treatment of epilepsy with cognitive dysfunction. Baijin pills have a positive clinical effect on patients with epilepsy and cognitive dysfunction.
